Depression

ClinicalAugust 4, 2026

Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) Initiated

A Phase I trial is underway to evaluate the safety and efficacy of high-density theta burst stimulation (hdTBS) in healthy adults.

StrategyAugust 3, 2026

FDA Grants Approval for Bupropion Hydrochloride by Yichang Humanwell

The FDA has granted approval for the ANDA220529 application for Bupropion Hydrochloride submitted by Yichang Humanwell.

RegulatoryAugust 2, 2026

FDA Submission Update for AXSOME's AUVELITY (NDA215430)

The FDA has received a supplemental application (NDA215430) for AUVELITY from AXSOME, with a standard review priority.

ClinicalAugust 2, 2026

Light Therapy Shows Promise for Depression in Pediatric HSCT Recipients

A clinical trial is evaluating the efficacy of blue light therapy for treating depression in children undergoing hematopoietic stem cell transplants.

ClinicalAugust 2, 2026

Study on Music's Impact on Emotion Recognition in Depressed Elderly Population

A study is assessing how positive music affects facial emotion recognition in elderly patients with depression.

ClinicalJuly 31, 2026

Virtual Reality for Cognitive Remediation in Elderly Patients with Depression

A study is investigating the acceptability of virtual reality as a cognitive remediation tool for elderly patients with depression.

StrategyJuly 29, 2026

FDA Grants AP Status for Aurobindo's Bupropion Hydrochloride

The FDA has granted Aurobindo Pharma's application for Bupropion Hydrochloride an Abbreviated New Drug Application (ANDA) status.

RegulatoryJuly 28, 2026

FDA Accepts Supplemental NDA for Biogen's Zuranolone (ZURZUVAE)

The FDA has accepted a supplemental NDA for Biogen's Zuranolone, indicating progress in its regulatory pathway.

RegulatoryJuly 26, 2026

FDA Accepts Supplemental Application for SPRAVATO (Esketamine)

The FDA has accepted a supplemental application for SPRAVATO, an esketamine-based treatment.

RegulatoryJuly 25, 2026

Aurobindo Pharma's Bupropion Hydrochloride ANDA216051 Receives AP Status

Aurobindo Pharma's ANDA216051 for Bupropion Hydrochloride has received Abbreviated Approval (AP) status from the FDA.

ClinicalJuly 18, 2026

Phase 2 Study of Ketamine-Induced phBOLD in Healthy Volunteers

A study is underway to evaluate the effects of ketamine on brain activity using pharmacoBOLD imaging in healthy volunteers.

ClinicalJuly 18, 2026

Study on MicroRNAs as Biomarkers for Suicidality in Adolescents

A clinical trial is underway to identify biomarkers for depression and suicidality in adolescents, focusing on neural-derived plasma exosomal microRNAs.

CompetitiveJuly 17, 2026

Lilly to acquire AtaiBeckley to enhance treatment-resistant depression therapies

Eli Lilly is acquiring AtaiBeckley to advance therapies targeting treatment-resistant depression.

RegulatoryJuly 11, 2026

FDA Acceptance of Supplement for AUVELITY by AXSOME

The FDA has accepted a supplemental application for AUVELITY, which includes bupropion hydrochloride and dextromethorphan hydrobromide.

ClinicalJuly 11, 2026

NIMH Study on Adolescent Depression Aims to Enhance Treatment Understanding

The NIMH is conducting a study to explore causes and treatments for depression in adolescents aged 11-17, comparing those with and without mental health diagnoses.

ClinicalJuly 11, 2026

Phase I Trial of Ammoxetine Hydrochloride in Hepatic Impairment Patients

A Phase I clinical trial is underway to evaluate the pharmacokinetics and safety of ammoxetine hydrochloride in patients with varying degrees of hepatic impairment.

ClinicalJuly 6, 2026

Psilocybin Therapy Shows Promise for Depression in Parkinson's Disease

A clinical trial is underway to evaluate the efficacy of psilocybin therapy in patients with Parkinson's Disease and depression.

RegulatoryJuly 5, 2026

FDA Accepts Supplemental NDA for Zuranolone (ZURZUVAE) by Biogen

The FDA has accepted a supplemental NDA for Zuranolone (ZURZUVAE) submitted by Biogen.

RegulatoryJune 30, 2026

FDA Accepts Supplement for SPRAVATO (Esketamine) by Janssen

The FDA has accepted a supplemental application for SPRAVATO, an esketamine-based treatment.

RegulatoryJune 27, 2026

FDA Approves ANDA for Bupropion Hydrochloride by Macleods

The FDA has approved ANDA218567 for Bupropion Hydrochloride submitted by Macleods Pharmaceuticals.

ClinicalJune 11, 2026

Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated

A pilot trial is evaluating a digitally enhanced stepped-care approach for treating depression in primary care settings.

RegulatoryJune 10, 2026

FDA Accepts Supplement for SPRAVATO (Esketamine Hydrochloride)

The FDA has accepted a supplemental application for SPRAVATO, indicating ongoing development and potential label expansion.

RegulatoryJune 7, 2026

Alembic's Duloxetine Hydrochloride Supplement Receives AP Status from FDA

Alembic's application for Duloxetine Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

Companies

Assets

Recent signals(23)